

Long Non-Coding RNA EGOT Promotes the Malignant Phenotypes of Hepatocellular Carcinoma Cells and Increases the Expression of HMGA2 via Down-Regulating miR-33a-5p [Retraction]

Wu S, Ai H, Zhang K, Yun H, Xie F. *Onco Targets Ther.* 2019;12:11623–11635.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figures 2, 3 and 6. Specifically,

- Figure 2E, si-RNA-NC appears to have been duplicated with the same image for Figure 6G, EGOT/miR-33a-5p which has been rotated.
- Figure 2E, siRNA-EGOT-1 appears to have been duplicated with the same image for Figure 3F, EGOT which has been rotated.
- Figure 2F, si-RNA-NC appears to have been duplicated with the same image for Figure 3E, lncRNA-NC which has been rotated.
- Figure 2F, si-RNA-NC appears to have been duplicated with the same image for Figure 6G, NC which has been rotated.
- Figure 2F, siRNA-EGOT-1 appears to have been duplicated with the same image for Figure 3F, lncRNA-NC.
- Figure 2F, siRNA-EGOT-1 appears to have been duplicated with the same image for Figure 6H, EGOT/miR-33a-5p which has been rotated.
- Figure 3E, lncRNA-NC appears to have been duplicated with the same image for Figure 6G, NC which has been rotated.
- Figure 3F, lncRNA-NC appears to have been duplicated with the same image for Figure 6H, EGOT/miR-33a-5p.

The authors did not respond to our queries and the Editor requested to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.S392090>

OncoTargets and Therapy 2022;15:1121

1121

Received: 3 October 2022
Accepted: 3 October 2022
Published: 5 October 2022

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).